SK8332002A3 - Novel processes for making- and a new crystalline form of leflunomide - Google Patents

Novel processes for making- and a new crystalline form of leflunomide Download PDF

Info

Publication number
SK8332002A3
SK8332002A3 SK833-2002A SK8332002A SK8332002A3 SK 8332002 A3 SK8332002 A3 SK 8332002A3 SK 8332002 A SK8332002 A SK 8332002A SK 8332002 A3 SK8332002 A3 SK 8332002A3
Authority
SK
Slovakia
Prior art keywords
leflunomide
solvent
form iii
solution
crystals
Prior art date
Application number
SK833-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Ilya Avrutov
Neomi Gershon
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SK8332002A3 publication Critical patent/SK8332002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
SK833-2002A 1999-12-16 2000-12-14 Novel processes for making- and a new crystalline form of leflunomide SK8332002A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17123799P 1999-12-16 1999-12-16
US17122899P 1999-12-16 1999-12-16
US18264700P 2000-02-15 2000-02-15
US20241600P 2000-05-08 2000-05-08
PCT/US2000/033866 WO2001043742A1 (en) 1999-12-16 2000-12-14 Novel processes for making- and a new crystalline form of- leflunomide

Publications (1)

Publication Number Publication Date
SK8332002A3 true SK8332002A3 (en) 2003-04-01

Family

ID=27496942

Family Applications (1)

Application Number Title Priority Date Filing Date
SK833-2002A SK8332002A3 (en) 1999-12-16 2000-12-14 Novel processes for making- and a new crystalline form of leflunomide

Country Status (15)

Country Link
US (3) US6610718B2 (cs)
EP (1) EP1242077A4 (cs)
JP (1) JP2003517011A (cs)
KR (1) KR20020067545A (cs)
CN (1) CN1411373A (cs)
AU (1) AU779931B2 (cs)
CA (1) CA2397601A1 (cs)
CZ (1) CZ20022000A3 (cs)
HR (2) HRP20020521A2 (cs)
HU (1) HUP0204069A3 (cs)
IL (1) IL149792A0 (cs)
PL (1) PL356243A1 (cs)
SK (1) SK8332002A3 (cs)
WO (1) WO2001043742A1 (cs)
YU (1) YU45102A (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
JP2003517011A (ja) * 1999-12-16 2003-05-20 テバ ファーマシューティカル インダストリーズ リミティド レフルノミドの新規な製法及び新しい結晶形態
WO2001051089A1 (de) * 2000-01-13 2001-07-19 Merck Patent Gmbh Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
YU61602A (sh) * 2000-02-15 2006-01-16 Teva Pharmaceutical Industries Ltd. Postupak za dobijanje leflunomida
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
WO2008040149A1 (en) * 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
AU2008315757A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・［ユーケー］・リミテッド ボセンタンの製造方法
AU2009321375A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited HPLC method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
JP2016537365A (ja) 2013-11-15 2016-12-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
US11801232B2 (en) * 2019-11-27 2023-10-31 Yale University Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
ATE151633T1 (de) * 1990-05-18 1997-05-15 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden- cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
EP0933633A1 (en) * 1997-12-11 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Process for obtaining L-dihydroorotic acid and use thereof
US7691890B2 (en) * 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
WO2001000622A1 (en) * 1999-06-25 2001-01-04 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
JP2003517011A (ja) * 1999-12-16 2003-05-20 テバ ファーマシューティカル インダストリーズ リミティド レフルノミドの新規な製法及び新しい結晶形態
YU61602A (sh) * 2000-02-15 2006-01-16 Teva Pharmaceutical Industries Ltd. Postupak za dobijanje leflunomida
WO2001072298A1 (en) * 2000-03-27 2001-10-04 The General Hospital Corporation Treatments for immune-mediated ear disorders
US20020077485A1 (en) * 2000-08-14 2002-06-20 Ilya Avrutov Micronized leflunomide
PT1491524E (pt) * 2000-08-24 2009-04-16 Univ Tennessee Res Foundation Moduladores selectivos do receptor androgénico e processos para a sua utilização
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005018697A2 (en) * 2003-08-13 2005-03-03 Medtronic, Inc. Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods
JP2007502281A (ja) * 2003-08-13 2007-02-08 メドトロニック・インコーポレーテッド 混和性ポリマー配合物を含む活性剤放出系、医療機器、及び方法
WO2005023201A2 (en) * 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis

Also Published As

Publication number Publication date
CA2397601A1 (en) 2001-06-21
CN1411373A (zh) 2003-04-16
EP1242077A1 (en) 2002-09-25
US20050004191A1 (en) 2005-01-06
CZ20022000A3 (cs) 2003-02-12
EP1242077A4 (en) 2006-01-04
HRP20020521A2 (en) 2004-08-31
AU2578801A (en) 2001-06-25
US20010031878A1 (en) 2001-10-18
JP2003517011A (ja) 2003-05-20
KR20020067545A (ko) 2002-08-22
HUP0204069A3 (en) 2005-01-28
PL356243A1 (en) 2004-06-28
AU779931B2 (en) 2005-02-17
US6806373B2 (en) 2004-10-19
YU45102A (sh) 2006-01-16
WO2001043742A1 (en) 2001-06-21
US20030203952A1 (en) 2003-10-30
US6610718B2 (en) 2003-08-26
IL149792A0 (en) 2002-11-10
HRP20050176A2 (en) 2005-08-31
HUP0204069A2 (hu) 2003-04-28

Similar Documents

Publication Publication Date Title
AU2002366383B2 (en) Polymorphs of clopidogrel hydrogensulfate
CA2651353C (en) Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form .alpha.
SK8332002A3 (en) Novel processes for making- and a new crystalline form of leflunomide
KR20030017569A (ko) 카르베딜올
US6767913B2 (en) Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7977348B2 (en) Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2021019448A1 (en) Process for the preparation of transthyretin dissociation inhibitor
US8134032B2 (en) Crystalline modifications of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CN108602772B (zh) 1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺盐新晶型
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
EP1257270B1 (en) A method for synthesizing leflunomide
US20080090833A1 (en) Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha
CA2437402A1 (en) New crystal forms of oxcarbazepine and processes for their preparation
WO2012090221A1 (en) Novel salts of imatinib
CN111732586B (zh) 含炔基化合物盐的晶型、制备方法及应用
KR20090014225A (ko) （ｒ）-5-（2-아미노에틸）-1-（6,8-디플루오로크로만-3-일）-1,3-디히드로이미다졸-티온 히드로클로라이드의 다형체
EP2072510A1 (en) Crystalline form of azelastine
AU2005202109A1 (en) Novel processes for making- and a new crystalline form of- leflunomide
WO2018042320A1 (en) Salts of betrixaban and processes for preparation thereof
KR20040017817A (ko) 페닐에탄올아민의 결정질 형태, 이의 제조 방법 및 이를포함하는 제약 조성물
EP4355737A1 (en) Polymorphs of 2-(3,5-dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid
WO2010010058A1 (en) Method of preparing anhydrous alfusozin hydrochloride
WO2014009969A2 (en) Novel polymorphs of azilsartan